More than four decades ago, Lynn Frohnmayer was a mother searching for answers after learning that three of her five children had Fanconi anemia. There was no roadmap and no established network of families or experts. Information was scarce, treatments were limited, and the future her family had been given was devastating.
Directory
Jeffrey Siegel
Executive Director, Translational Medicine, Inflammation Clinical Research | MD
Jeffrey Siegel, MD, is Executive Director, Translational Medicine, Inflammation Clinical Research at Gilead Sciences. He received his medical degree from Yale University School of Medicine, internship and residency training at the University Hospitals of Cleveland, clinical fellowship training in Rheumatology at University Hospitals of Cleveland and basic science research training at the NIH in Immunology and signal transduction. After fellowship, he joined the Naval Medical Research Institute for 5 years where he served as Branch Head, Signal Transduction. He then joined the FDA and was there for 14 years, serving as Supervisory Medical Officer, Clinical Team Leader in Rheumatology. He previously worked at Genentech as Senior Group Medical Director in the Product Development Immunology department.
The Latest
News & Events
What I hope for most is greater awareness, earlier diagnosis, access to treatment and support for families affected by FA in Malaysia. I hope no other mother has to go through what I went through, feeling confused, unprepared and alone while watching her children struggle with FA.
The Fanconi Cancer Foundation is pleased to recognize Dominika as the first-place recipient of the 2026 Winn/Byrd Award for Adults with FA. Dexter Sherrell received the second-place award for his work connecting people affected by rare diseases with researchers, health care professionals and advocates.